Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TociCCAre
2024-515956-19-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chondrocalcinosis (CPPD) comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Change in overall pain visual analogue scale at month 4. Planned start Aug 2025; status: authorised.
02
Drugs
tocilizumab
03
Conditions
chondrocalcinosis (CPPD)
Beyond the preview
Go deeper on 2024-515956-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515956-19-00.